The stat3 paradox: A killer and an oncogene

Molecular and Cellular Endocrinology

Volumn 382, Issue 1, 2014, Pages 603-611

  Resemann, Henrike K ^a   Watson, Christine J ^a   Lloyd Lewis, Bethan ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Breast cancer; Involution; Mammary gland; Microenvironment; Stat3

Indexed keywords

STAT3 PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST DEVELOPMENT; BREAST EPITHELIUM; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL TYPE; EPITHELIUM CELL; HUMAN; INFLAMMATION; INVOLUTION; LACTATION; MICROENVIRONMENT; NONHUMAN; ONCOGENE; PARACRINE SIGNALING; PREGNANCY; PRIORITY JOURNAL; PROTEIN FUNCTION; STEM CELL; TRANSCRIPTION INITIATION;

BREAST CANCER; INVOLUTION; MAMMARY GLAND; MICROENVIRONMENT; STAT3;

ANIMALS; CARCINOGENESIS; CELL DEATH; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; ONCOGENES; STAT3 TRANSCRIPTION FACTOR;

EID: 84888287996     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.06.029     Document Type: Article

References (140)

1. Abell K., Bilancio A., et al. Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. Nat. Cell Biol. 2005, 7(4):392-398.
2. Akira S., Nishio Y., et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994, 77(1):63-71.
3. Alvarez J.V., Febbo P.G., et al. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 2005, 65(12):5054-5062.
4. Avalle L., G.Regis, et al. Universal and Specific Functions of STAT3 in Solid Tumours. Jak-Stat Signaling: From Basics to Disease 2012, 305-333. Springer Vienna. T. Decker, M. Muller (Eds.).
5. Avalle L., Pensa S., et al. STAT1 and STAT3 in tumorigenesis: a matter of balance. JAK-STAT 2012, 1(2):65-72.
6. Azare J., Leslie K., et al. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin 6. Mol. Cell. Biol. 2007, 27(12):4444-4453.
7. Baltayiannis G., Baltayiannis N., et al. Suppressors of cytokine signaling as tumor repressors. Silencing of SOCS3 facilitates tumor formation and growth in lung and liver. J. BUON. 2008, 13:263-265.
8. Barbieri I., Pensa S., et al. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res. 2010, 70:2558-2567.
9. Barbieri I., Quaglino E., et al. Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene. Mol. Carcinog. 2010, 49:114-120.
10. Barry S.P., Townsend P.A., et al. STAT3 deletion sensitizes cells to oxidative stress. Biochem. Biophys. Res. Commun. 2009, 385(3):324-329.
11. Berclaz G., Altermatt H.J., et al. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int. J. Oncol. 2001, 19:1155-1160.
12. Binai N.A., Damert A., et al. Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells. Int. J. Cancer 2010, 127:55-66.
13. Bollrath J., Phesse T.J., et al. Gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
14. Bromberg J., Wang T.C. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009, 15(2):79-80.
15. Bromberg J.F., Horvath C.M., et al. Stat3 activation is required for cellular transformation by v-Src. Mol. Cell Biol. 1998, 18(5):2553-2558.
16. Buck M.R., Karustis D.G., et al. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem. J. 1992, 282:273-278.
17. Burke M.A., Hutter D., et al. Cathepsin L plays an active role in involution of the mouse mammary gland. Developmental Dynamics: an Official Publication of the American Association of Anatomists 2003, 227(3):315-322.
18. Cesen M.H., Pegan K., et al. Lysosomal pathways to cell death and their therapeutic applications. Exp. Cell Res. 2012, 318(11):1245-1251.
19. Chan K.S., Sano S., et al. Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis. Oncogene 2008, 27:1087-1094.
20. Chapman R.S., Lourenco P.C., et al. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev. 1999, 13(19):2604-2616.
21. Chavey C., Bibeau F., et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res: BCR 2007, 9:R15.
22. Cheng F., Wang H.-W., et al. A critical role for Stat3 signaling in immune tolerance. Immunity 2003, 19(3):425-436.
23. Cheng G.Z., Zhang W.Z., et al. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J. Biol. Chem. 2008, 283:14665-14673.
24. Clarkson R.W., Wayland M.T., et al. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res.: BCR 2004, 6(2):R92-109.
25. Clarkson R.W., Boland M.P., et al. The genes induced by signal transducer and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells define the roles of these STATs in mammary development. Mol. Endocrinol. 2006, 20(3):675-685.
26. Darnell J.E., Kerr I.M., et al. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264(5164):1415-1421.
27. Dauer D.J., Ferraro B., et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005, 24(21):3397-3408.
28. Dechow T.N., Pedranzini L., et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Nat. Acad. Sci. USA 2004, 101(29):10602-10607.
29. Demaria M., Giorgi C., et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY). 2010, 2:823-842.
30. Diaz N., Minton S., et al. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin. Cancer Res. 2006, 12:20-28.
31. El Kasmi K.C., Holst J., et al. General nature of the STAT3-activated anti-inflammatory response. J. Immunol. 2006, 177(11):7880-7888.
32. Evans M.K., Yu C.R., et al. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene 2007, 26(13):1941-1948.
33. Garcia R., Yu C.L., et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 1997, 8:1267-1276.
34. Garcia R., Bowman T.L., et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20:2499-2513.
35. Gariboldi M.B., Ravizza R., et al. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett. 2007, 258:181-188.
36. Gough D.J., Corlett A., et al. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009, 324:1713-1716.
37. Green K.A., Lund L.R. ECM degrading proteases and tissue remodelling in the mammary gland. BioEssays: news and reviews in molecular. Cell. Dev. Biol. 2005, 27(9):894-903.
38. Gritsko T., Williams A., et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 2006, 12:11-19.
39. Grivennikov S., Karin E., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
40. Haricharan, S., Li, Y., 2013. STAT signaling in mammary gland differentiation, cell survival and tumorigenesis. Mol. Cell. Endocrinol., this issue.
41. Hsieh F.-C., Cheng G., et al. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem. Biophys. Res. Commun. 2005, 335:292-299.
42. Hughes K., Wickenden J.A., et al. Conditional deletion of Stat3 in mammary epithelium impairs the acute phase response and modulates immune cell numbers during post-lactational regression. J. Pathol. 2012, 227(1):106-117.
43. Humphreys R.C., Bierie B., et al. Deletion of Stat3 blocks mammary gland involution and extends functional competence of the secretory epithelium in the absence of lactogenic stimuli. Endocrinology 2002, 143(9):3641-3650.
44. Hynes N.E., Watson C.J. Mammary gland growth factors: roles in normal development and in cancer. Cold Spring Harbor Perspectives in Biology 2010, 2(8).
45. Iliopoulos D., Jaeger S.A., et al. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 2010, 39:493-506.
46. Iliopoulos D., Hirsch H.A., et al. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA 2011, 108:1397-1402.
47. Jensen B.V., Johansen J.S., et al. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin. Cancer Res. 2003, 9(12):4423-4434.
48. Jiang X.P., Yang D.C., et al. Reduction in serum IL-6 after vacination of breast cancer patients with tumour-associated antigens is related to estrogen receptor status. Cytokine 2000, 12:458-465.
49. Kallunki T., Olsen O.D., et al. Cancer-associated lysosomal changes: friends or foes?. Oncogene 2012, 32:1995-2004.
50. Katz M., Amit I., et al. A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat. Cell Biol. 2007, 9:961-969.
51. Kim J.E., Kim H.S., et al. LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression. Exp. Mol. Med. 2008, 40:514-522.
52. Kirkegaard T., Jaattela M. Lysosomal involvement in cell death and cancer. Biochim. Biophys. Acta 2009, 1793(4):746-754.
53. Kozłowski L., Zakrzewska I., et al. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz. Akad. Med. Bialymst. 2003, 48:82-84.
54. Krause A., Scaletta N., et al. Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J. Immunol. 2002, 169(11):6610-6616.
55. Kreuzaler P., Watson C.J. Killing a cancer: what are the alternatives?. Nat. Rev. Cancer. 2012, 12(4):411-424.
56. Kreuzaler P.A., Staniszewska A.D., et al. Stat3 controls lysosomal-mediated cell death in vivo. Nat. Cell Biol. 2011, 13(3):303-309.
57. Kritikou E.A., Sharkey A., et al. A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland. Development 2003, 130(15):3459-3468.
58. Kroemer G., Jaattela M. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer 2005, 5(11):886-897.
59. Kroy D.C., Beraza N., et al. Lack of interleukin-6/glycoprotein 130/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice. Hepatology 2010, 51(2):463-473.
60. Kunigal S., Lakka S.S., et al. Stat3-siRNA induces fas-mediated apoptosis in vitro and in vivo in breast cancer. Int. J. Oncol. 2009, 34:1209-1220.
61. Lee H., Deng J., et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat. Med. 2010, 1421-1428.
62. Leslie K., Lang C., et al. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res. 2006, 66:2544-2552.
63. Levy D.E., Darnell J.E. STATs: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3(9):651-662.
64. Levy D.E., Inghirami G. STAT3: A multifaceted oncogene. Proc. Nat. Acad. Sci. 2006, 103(27):10151-10152.
65. Li Y., Du H., et al. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res. 2007, 67:8494-8503.
66. Li N., Grivennikov S.I., et al. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 2011, 19(4):429-431.
67. Liu X., Robinson G.W., et al. Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Mol. Endocrinol. 1996, 10(12):1496-1506.
68. Liu K., Liang C., et al. Sle1ab mediates the aberrant activation of STAT3 and Ras-ERK signaling pathways in B lymphocytes. J. Immunol. 2005, 174(3):1630-1637.
69. Liu L., Gao Y., et al. Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene 2006, 25:4904-4912.
70. Liu A., Liu Y., et al. XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. PLoS ONE 2012, 7(10):e46624.
71. Lo H.W., Hsu S.C., et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 2007, 67(19):9066-9076.
72. Lund L.R., Romer J., et al. Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 1996, 122(1):181-193.
73. Luo Y.P., Zhou H., et al. The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression. Oncogene 2010, 29:662-673.
74. Lyons T., Schedin P., et al. Pregnancy and breast cancer: when they collide. J. Mammary Gland Biol. Neoplasia 2009, 14(2):87-98.
75. Lyons T.R., O'Brien J., et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat. Med. 2011, 17(9):1109-1115.
76. Manning D.L., Robertson J.F., et al. Oestrogen-regulated genes in breast cancer: association of pLIV1 with lymph node involvement. Eur. J. Cancer 1994, 30A(5):675-678.
77. Marotta L.L.C., Almendro V., et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. J. Clin. Investig. 2011, 121(7):2723-2735.
78. McCaffrey L.M., Montalbano J., et al. Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis. Cancer Cell 2012, 22(5):601-614.
79. McDaniel S.M., Rumer K.K., et al. Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am. J. Pathol. 2006, 168(2):608-620.
80. Minami M., Inoue M., et al. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc. Nat. Acad. Sci. USA 1996, 93(9):3963-3966.
81. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6(10):764-775.
82. Nakajima K., Yamanaka Y., et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 1996, 15(14):3651-3658.
83. Ng D.C.H., Lin B.H., et al. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J. Cell Biol. 2006, 172:245-257.
84. Nguyen A.V., Pollard J.W. Transforming growth factor beta3 induces cell death during the first stage of mammary gland involution. Development 2000, 127(14):3107-3118.
85. Niu G., Wright K., et al. Constitutive STAT3 activity up-regulates VEGF expression and tumour angiogenesis. Oncogene 2002, 21:2000-2008.
86. Niu G., Wright K.L., et al. Role of Stat3 in regulating p53 expression and function. Mol. Cell. Biol. 2005, 25(17):7432-7440.
87. Park J., Kusminski C.M., et al. Leptin receptor signaling supports cancer cell metabolism through suppression of mitochondrial respiration in vivo. Am. J. Pathol. 2010, 177:3133-3144.
88. Pensa S., Regis G., et al. STAT1 and STAT3 in Tumorigenesis: Two Sides of the Same Coin?. JAK-STAT Pathway in Disease 2008, 100-121. Landes Biocience, Austin.
89. Pensa S., Watson C.J., et al. Stat3 and the inflammation/acute phase response in involution and breast cancer. J. Mammary Gland Biol. Neoplasia 2009, 14(2):121-129.
90. Philp J.A., Burdon T.G., et al. Differential activation of STATs 3 and 5 during mammary gland development. FEBS Lett. 1996, 396(1):77-80.
91. Quaglino A., Schere-Levy C., et al. Mouse mammary tumors display Stat3 activation dependent on leukemia inhibitory factor signaling. Breast Cancer Res.: BCR. 2007, 9:R69.
92. Radisky D.C., Hartmann L.C. Mammary involution and breast cancer risk: transgenic models and clinical studies. J. Mammary Gland Biol. Neoplasia 2009, 14(2):181-191.
93. Ranger J.J., Levy D.E., et al. Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res. 2009, 69:6823-6830.
94. Raz R., Lee C.-K., et al. Essential role of STAT3 for embryonic stem cell pluripotency. Proc. Nat. Acad. Sci. 1999, 96(6):2846-2851.
95. Salgado R., Junius S., et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int. J. Cancer 2003, 103:642-646.
96. Sano S., Itami S., et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 1999, 18(17):4657-4668.
97. Sansone P., Storci G., et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 2007, 117:3988-4002.
98. Saxena N.K., Vertino P.M., et al. Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J. Biol. Chem. 2007, 282:13316-13325.
99. Schafer M., Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat. Rev. Mol. Cell Biol. 2008, 9(8):628-638.
100. Schere-Levy C., Buggiano V., et al. Leukemia inhibitory factor induces apoptosis of the mammary epithelial cells and participates in mouse mammary gland involution. Exp. Cell Res. 2003, 282(1):35-47.
101. Schindler C., Levy D.E., et al. JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 2007, 282(28):20059-20063.
102. Selander K.S., Li L., et al. Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res. 2004, 64:6924-6933.
103. Shulga N., Pastorino J.G. GRIM-19-mediated translocation of STAT3 to mitochondria is necessary for TNF-induced necroptosis. J. Cell Sci. 2012, 125(Pt 12):2995-3003.
104. Siddiquee K., Zhang S., et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Nat. Acad. Sci. USA 2007, 104:7391-7396.
105. Silva C.M. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004, 23(48):8017-8023.
106. Skov S., Nielsen M., et al. Activation of Stat-3 is involved in the induction of apoptosis after ligation of major histocompatibility complex class I molecules on human jurkat T cells. Blood 1998, 91(10):3566-3573.
107. Song Y., Qian L., et al. Fra-1 and Stat3 synergistically regulate activation of human MMP-9 gene. Mol. Immunol. 2008, 45(1):137-143.
108. Stein T., Morris J.S., et al. Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res.: BCR 2004, 6(2):R75-91.
109. Sullivan N.J., Sasser A.K., et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009, 28:2940-2947.
110. Sun Z., Yao Z., et al. An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer. Immunobiology 2006, 211:199-209.
111. Takeda K., Noguchi K., et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Nat. Acad. Sci. 1997, 94(8):3801-3804.
112. Takeda K., Kaisho T., et al. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol. 1998, 161(9):4652-4660.
113. Thangaraju M., Rudelius M., et al. C/EBPdelta is a crucial regulator of pro-apoptotic gene expression during mammary gland involution. Development 2005, 132(21):4675-4685.
114. Tiffen P.G., Omidvar N., et al. A dual role for oncostatin M signaling in the differentiation and death of mammary epithelial cells in vivo. Mol. Endocrinol. 2008, 22(12):2677-2688.
115. Tsuyada A., Chow A., et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012, 72(11):2768-2779.
116. Turkson J., Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000, 19:6613-6626.
117. Urieli-Shoval S., Linke R.P., et al. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr. Opin. Hematol. 2000, 7(1):64-69.
118. Vallania F., Schiavone D., et al. Genome-wide discovery of functional transcription factor binding sites by comparative genomics: the case of Stat3. Proc. Nat. Acad. Sci. 2009, 106(13):5117-5122.
119. Vasiljeva O., Papazoglou A., et al. Tumor cell, ÄìDerived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 2006, 66(10):5242-5250.
120. Walker, S.R., Xiang, M., et al. 2013. Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol. Cell. Endocrinol., this issue.
121. Walker S.R., Nelson E.A., et al. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol. Cancer Res. 2009, 7(6):966-976.
122. Wan J., Fu A.K.Y., et al. Tyk2/STAT3 signaling mediates beta-Amyloid-induced neuronal cell death: implications in Alzheimer's disease. J. Neurosci. 2010, 30(20):6873-6881.
123. Wang T., Niu G., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 2004, 10:48-54.
124. Watson C.J., Khaled W.T. Mammary development in the embryo and adult: a journey of morphogenesis and commitment. Development 2008, 135(6):995-1003.
125. Watson C.J., Kreuzaler P.A. Remodeling mechanisms of the mammary gland during involution. Int. J. Dev. Biol. 2011, 55(7-9):757-762.
126. Wegrzyn J., Potla R., et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009, 323:793-797.
127. Xie T.-X., Wei D., et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004, 23:3550-3560.
128. Yadav A., Kumar B., et al. IL-6 promotes head and neck tumor metastasis by inducing epithelial, äìmesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol. Cancer Res. 2011, 9(12):1658-1667.
129. Yamanaka Y., Nakajima K., et al. Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J. 1996, 15(7):1557-1565.
130. Yamashita S., Miyagi C., et al. Stat3 controls cell movements during zebrafish gastrulation. Dev. Cell 2002, 2(3):363-375.
131. Yamashita S., Miyagi C., et al. Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer. Nature 2004, 429(6989):298-302.
132. Yang J., Liao D., et al. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem. Cells 2013, 31(2):248-258.
133. Yeh Y.-T., Ou-Yang F., et al. STAT3 ser727 phosphorylation and its association with negative estrogen receptor status in breast infiltrating ductal carcinoma. Int. J. Cancer 2006, 118(12):2943-2947.
134. Yoshimura A. Negative regulation of cytokine signaling. Clin. Rev. Allergy Immunol. 2005, 28:205-220.
135. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 2004, 4(2):97-105.
136. Yu C.L., Meyer D.J., et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995, 269(5220):81-83.
137. Yu H., Pardoll D., et al. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9(11):798-809.
138. Zhang G.J., Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999, 19:1427-1432.
139. Zhang X., Yue P., et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc. Nat. Acad. Sci. 2012, 109(24):9623-9628.
140. Zhao L., Melenhorst J.J., et al. Loss of interleukin 6 results in delayed mammary gland involution: a possible role for mitogen-activated protein kinase and not signal transducer and activator of transcription 3. Mol. Endocrinol. 2002, 16(12):2902-2912.